Health policy versus industrial policy in the pharmaceutical sector: the case of Canada
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Comanor, William S, 1986. "The Political Economy of the Pharmaceutical Industry," Journal of Economic Literature, American Economic Association, vol. 24(3), pages 1178-1217, September.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Morgan, Steve & McMahon, Meghan & Greyson, Devon, 2008. "Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia," Health Policy, Elsevier, vol. 87(2), pages 133-145, August.
- Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000.
"Review of the literature on reference pricing,"
Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
- Guillem López & Jaume Puig, 1999. "Review of the literature on reference pricing," Working Papers, Research Center on Health and Economics 362, Department of Economics and Business, Universitat Pompeu Fabra.
- Guillem López & Jaume Puig, 1999. "Review of the literature on reference pricing," Economics Working Papers 362, Department of Economics and Business, Universitat Pompeu Fabra.
- Diogo Ferraz & Fernanda P. S. Falguera & Enzo B. Mariano & Dominik Hartmann, 2021. "Linking Economic Complexity, Diversification, and Industrial Policy with Sustainable Development: A Structured Literature Review," Sustainability, MDPI, vol. 13(3), pages 1-29, January.
- Fattore, Giovanni & Jommi, Claudio, 1998. "The new pharmaceutical policy in Italy," Health Policy, Elsevier, vol. 46(1), pages 21-41, October.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Tapon, Francis & Cadsby, Charles Bram, 1996. "The optimal organization of research: evidence from eight case studies of pharmaceutical firms," Journal of Economic Behavior & Organization, Elsevier, vol. 31(3), pages 381-399, December.
- Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2013.
"Technological Regimes and Demand Structure in the Evolution of the Pharmaceutical Industry,"
Economic Complexity and Evolution, in: Andreas Pyka & Esben Sloth Andersen (ed.), Long Term Economic Development, edition 127, pages 61-94,
Springer.
- Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2012. "Technological regimes and demand structure in the evolution of the pharmaceutical industry," Journal of Evolutionary Economics, Springer, vol. 22(4), pages 677-709, September.
- Christian Garavaglia & Michele Pezzoni & Luigi Orsenigo & Franco Malerba, 2012. "Technological regimes and demand structure in the evolution of the pharmaceutical industry," Post-Print halshs-01074513, HAL.
- Karel Cool & Ingemar Dierickx, 1993. "Abstract," Strategic Management Journal, Wiley Blackwell, vol. 14(1), pages 47-59, January.
- Eleanor Morgan, 2001. "Innovation and Merger Decisions in the Pharmaceutical Industry," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 19(2), pages 181-197, September.
- Rizzo, John A, 1999. "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs," Journal of Law and Economics, University of Chicago Press, vol. 42(1), pages 89-116, April.
- Kane, Nancy M., 1997. "Pharmaceutical cost containment and innovation in the United States," Health Policy, Elsevier, vol. 41(Supplemen), pages 71-89, September.
- Roberts, Peter W. & McEvily, Susan, 2005. "Product-line expansion and resource cannibalization," Journal of Economic Behavior & Organization, Elsevier, vol. 57(1), pages 49-70, May.
- Jie Chen & John Rizzo, 2012. "Pricing dynamics and product quality: the case of antidepressant drugs," Empirical Economics, Springer, vol. 42(1), pages 279-300, February.
- Regan, Tracy L., 2008.
"Generic entry, price competition, and market segmentation in the prescription drug market,"
International Journal of Industrial Organization, Elsevier, vol. 26(4), pages 930-948, July.
- Tracy L. Regan, 2007. "Generic entry, price competition, and market segmentation in the prescription drug market," Working Papers 2010-7, University of Miami, Department of Economics.
- Nicolas Iung & Frédéric Rupprecht, 1998. "Le marché pharmaceutique français : la prépondérance des produits-phares," Économie et Statistique, Programme National Persée, vol. 312(1), pages 21-33.
- Manning, Richard L, 1997. "Products Liability and Prescription Drug Prices in Canada and the United States," Journal of Law and Economics, University of Chicago Press, vol. 40(1), pages 203-243, April.
- Lynne G. Zucker & Michael R. Darby, 1995. "Present at the Revolution: Transformation of Technical Identity for a Large Incumbent Pharmaceutical Firm After the Biotechnological Breakthrough," NBER Working Papers 5243, National Bureau of Economic Research, Inc.
- Zhe Ren & Ingrid Sketris & Kuan Xu, 2012. "Brand-Name and Generic Drug Pricing in a Regulated Environment: Findings from Canada," Working Papers daleconwp2011-04, Dalhousie University, Department of Economics.
- F. M. Scherer, 1993. "Pricing, Profits, and Technological Progress in the Pharmaceutical Industry," Journal of Economic Perspectives, American Economic Association, vol. 7(3), pages 97-115, Summer.
- Peter W Roberts, 2001. "Innovation and firm-level persistent profitability: a Schumpeterian framework," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 22(4-5), pages 239-250.
- Wogart, Jan Peter, 2006. "Multiple Interfaces of Big Pharma and the Change of Global Health Governance in the Face of HIV/AIDS," GIGA Working Papers 24, GIGA German Institute of Global and Area Studies.
- Stéphane Jacobzone, 1998. "Le rôle des prix dans la régulation du secteur pharmaceutique," Économie et Statistique, Programme National Persée, vol. 312(1), pages 35-53.
- Stuart J Graham, 2004. "Secrecy in the Shadow of Patenting: Firms Use of Continuation Patents, 1975-1994," Levine's Working Paper Archive 228400000000000035, David K. Levine.
- Lall Ramrattan & Michael Szenberg, 2006. "Global Competition and the United States Pharmaceutical Industry," The American Economist, Sage Publications, vol. 50(2), pages 65-82, October.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:41:y:1997:i:3:p:241-260. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.